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Abstract: It is increasingly appreciated that missense variants may not only alter protein structure
and function but may also influence pre-mRNA splicing and/or mRNA stability. Here we explore
this issue in the context of currently known SPINK1 missense variants using a full-length gene assay.
We demonstrated that 4 (17%) out of 24 variants tested significantly reduced pre-mRNA splicing
and/or stability as compared with the wild-type. However, since the strongest effect observed was a
23% reduction from normal, the contribution of SPINK1 missense variants to the clinical phenotype
through an impact on mRNA processing alone may be relatively minor compared with their effects
in relation to protein structure/function.
Keywords: chronic pancreatitis; full-length gene assay; minigene assay; missense variant;
mRNA stability; pre-mRNA splicing; SPINK1 gene
1. Introduction
Recently, it was reported that that up to 10% of known disease-associated missense variants alter
pre-mRNA splicing [1]. In addition, missense variant-containing transcripts may also be less stable
as compared to wild-type, if for example the variants facilitate the formation of alternative mRNA
secondary structures [2]. SPINK1 (encoding pancreatic secretory trypsin inhibitor; OMIM #167790)
is one of the most studied genes predisposing to chronic pancreatitis [3]. We have recently provided
both in vitro and in silico evidence [4] against a significant effect of the SPINK1 c.194G>A variant
on pre-mRNA splicing, contrary to previous claims by Beer and Sahin-Tóth [5]. The key difference
between these studies was that the former used a full-length gene assay to assess pre-mRNA splicing,
whereas the latter used a minigene assay; full-length gene assays are generally superior to minigene
assays because pre-mRNA splicing is highly dependent upon the genomic context [6]. We were thus
able to conclude that the pathogenic effect of the c.194G>A missense variant (p.Arg65Gln) was exerted
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exclusively via its impact on protein secretion, as previously reported [7,8], rather than through an
influence on pre-mRNA splicing.
Prompted, however, by the aforementioned publication of Soemedi et al. [1], we sought to analyze
the effect of all currently known SPINK1 missense variants on pre-mRNA splicing and/or mRNA
stability by means of our previously established full-length gene assay [4].
2. Materials and Methods
2.1. Mutagenesis
The 23 additional SPINK1 missense variants as well as three synonymous variants logged
in the Genetic Risk Factors in Chronic Pancreatitis database [9]; Table 1) were introduced
separately into the pcDNA3.1/V5-His-TOPO vector harboring the wild-type full-length 7-kb
SPINK1 genomic sequence (including all four exons plus the three introns of the gene [10])
with Agilent’s QuikChange II XL Site-Directed Mutagenesis Kit (Les Ulis, France), essentially
as previously described [11]. The sequences of the mutagenesis primers are available upon
request. The successful introduction of the desired variants was confirmed by direct sequencing;
the primers used for this purpose included 5′-TAATACGACTCACTATAGGG-3′ (for exon 1 variants),
5′-TGCCTGATTCATTTCCAGCAG-3′ (for exon 2 variants), 5′-TCAGAAGGGCCATAGGACTT-3′
(for exon 3 variants), and 5′-AGAGGCATCAGGAGCAAAAG-3′ (for exon 4 variants).
Table 1. Quantitative reverse-transcription PCR (RT-PCR) analyses of mRNA expression from HEK293T
cells transfected with SPINK1 missense variants.
Exon
Variant Relative mRNA Expression a Pathogenicity
Classification bNucleotide Change Amino Acid Change Mean± SD p-Value
Missense
1 c.26T>G p.Leu9Arg 94.3 ± 8.0 0.248 Unknown
1 c.29G>A p.Ser10Asn 80.0 ± 4.4 0.003 Non-pathogenic
1 c.36G>C p.Leu12Phe 96.4 ± 9.8 0.517 Non-pathogenic
1 c.41T>C p.Leu14Pro 91.5 ± 5.9 0.064 Pathogenic
1 c.41T>G p.Leu14Arg 103.6 ± 12.9 0.621 Pathogenic
3 c.101A>G p.Asn34Ser 103.8 ± 7.6 0.482 Non-pathogenic
3 c.110A>G p.Asn37Ser 99.0 ± 6.2 0.800 Non-pathogenic
3 c.123G>C p.Lys41Asn 97.0 ± 4.0 0.315 Pathogenic
3 c.126A>G p.Ile42Met 108.2 ± 9.4 0.270 Unknown
3 c.133C>T p.Pro45Ser 94.7 ± 6.0 0.266 Unknown
3 c.137T>A p.Val46Asp 100.1 ± 2.7 0.954 Unknown
3 c.143G>A p.Gly48Glu 106.0 ± 11.6 0.379 Pathogenic
3 c.150T>G p.Asp50Glu 98.8 ± 5.0 0.700 Pathogenic
3 c.160T>C p.Tyr54His 100.5 ± 15.7 0.953 Pathogenic
3 c.163C>T p.Pro55Ser 105.9 ± 8.4 0.355 Non-pathogenic
3 c.190A>G p.Asn64Asp 82.2 ± 4.1 0.017 Pathogenic
3 c.193C>T p.Arg65Trp 97.8 ± 4.7 0.505 Unknown
3 c.194G>A c p.Arg65Gln 108.5 ± 10.4 0.295 Pathogenic
4 c.198A>C p.Lys66Asn 97.5 ± 4.4 0.425 Pathogenic
4 c.199C>T p.Arg67Cys 77.1 ± 10.1 0.007 Pathogenic
4 c.200G>A p.Arg67His 94.3 ± 9.7 0.323 Pathogenic
4 c.203A>G p.Gln68Arg 87.4 ± 7.0 0.037 Protective
4 c.206C>T p.Thr69Ile 106.8 ± 7.1 0.240 Pathogenic
4 c.236G>T p.Cys79Phe 110.0 ± 4.5 0.062 Pathogenic
Synonymous
2 c.75C>T p.Ser25= 90.2 ± 8.1 0.093 Unknown
3 c.174C>T p.Cys58= 96.6 ± 4.2 0.291 Unknown
4 c.231G>A p.Gly77= 93.3 ± 8.3 0.297 Unknown
a Relative to the wild-type value, which was set to 100 (results from three to five independent transfection
experiments). SD, standard deviation. Variants whose expression levels were statistically different from wild-type
(i.e., p < 0.05) are highlighted in blue. b In accordance with the Genetic Risk Factors in Chronic Pancreatitis
database [9]. c Previously analyzed by means of the full-length gene assay [4].
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2.2. Cell Culture, Transfection, RNA Extraction, and Reverse Transcription
Human embryonic kidney 293T (HEK293T) cells were cultured in Dulbecco’s modified Eagle
medium with 10% fetal calf serum. Twenty-four hours prior to transfection, 3.5× 105 cells were seeded
per well of 6-well plates. For qualitative reverse transcription-PCR (RT-PCR) analyses (see Section 2.3),
1 µg wild-type or variant SPINK1 expression vector, mixed with 3 mL Lipofectamine 2000 Reagent
(Life Technologies, Courtaboeuf, France), was used for transfection per well. For quantitative RT-PCR
analyses (see Section 2.4), 500 ng wild-type or variant SPINK1 expression vector plus 500 ng pGL3-GP2
minigene [10] were mixed with 3 mL Lipofectamine 2000 Reagent for transfection. Forty-eight hours
after transfection, total RNA was extracted using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France).
Reverse transcription was performed with 1 µg total RNA and 20mer-oligo(dT) by means of the
SuperScript III Reverse Transcriptase kit (Life Technologies) in accordance with the manufacturer’s
instructions. The resulting complementary DNAs (cDNAs) were treated with 2U Ribonuclease H
(Life Technologies) at 37 ◦C for 20 min to degrade the remaining RNA.
2.3. Qualitative RT-PCR Analyses and Sequencing of the Resulting Products
Qualitative RT-PCR was performed in a 25-µL reaction mixture containing 12.5 µL HotStarTaq
Master Mix (Qiagen), 0.4 µM each primer (forward: 5′-GGAGACCCAAGCTGGCTAGT-3′,
located within the 5′-untranslated region encoded by the pcDNA3.1/V5-His-TOPO vector; reverse:
5′-AGACCGAGGAGAGGGTTAGG-3′, located within the V5 epitope sequence encoded by the
pcDNA3.1/V5-His-TOPO vector) and 1 µL cDNA. The PCR program had an initial denaturation
at 95 ◦C for 15 min, followed by 30 cycles of denaturation at 94 ◦C for 45 s, annealing at 58 ◦C for
45 s, extension at 72 ◦C for 5 min, with a final extension step at 72 ◦C for 10 min. PCR products
were cleaned by ExoSAP-IT (Life Technologies) and sequenced using the BigDye Terminator v1.1
Cycle Sequencing Kit (Life Technologies), the primer used for sequencing was the aforementioned
5′-GGAGACCCAAGCTGGCTAGT-3’.
2.4. Quantitative RT-PCR Analyses
These were performed essentially as previously described [10,12]. In brief, wild-type or variant
SPINK1 expression vector was co-transfected with the previously constructed pGL3-GP2 minigene [10].
The target (SPINK1) and reference (i.e., pGL3-GP2 minigene) genes were PCR-amplified separately;
SPINK1 expression was determined using pGL3-GP2 minigene expression as a reference by means of
the ∆∆Ct method in accordance with Pfaffl’s efficiency-corrected calculation model [13].
Quantitative RT-PCR was performed in a 25 µL mixture containing 12.5 µL HotStarTaq Master
Mix Kit (Qiagen), 1 µL 1:25 diluted cDNA, 0.5 µM SYTO9 (Life Technologies), and 0.3 µM each
primer; the primers for qualitative RT-PCR analyses of the SPINK1 gene (see Section 2.3) were
used for analyzing the SPINK1 gene whilst the primers used for analyzing the reference gene
were 5′-ACTGTTGGTAAAGCCACCAT-3′ (forward) and 5’-TGTATCTTATCATGTCTGCTCGAA-3’
(reverse). The PCR program had an initial denaturation step at 95 ◦C for 15 min, followed by 40
cycles of denaturation at 94 ◦C for 45 s, annealing at 55 ◦C for 30 s, and extension at 72 ◦C for 30 s.
Quantitative analysis of each RT-PCR amplification was performed in triplicate on a Lightcycler 480II
(Roche, Paris, France) using ‘relative quantification’ and ‘second derivative maxima’ options.
The difference between the expression levels of a SPINK1 variant and the wild-type sequence
(results from three to five independent transfection experiments) was assessed for significance by
the Student t-test. The difference was regarded as being statistically significant when the p-value
was ≤0.05.
3. Results and Discussion
Qualitative RT-PCR analyses of mRNAs from HEK293T cells transfected with the 23 missense
variants and 3 synonymous variants invariably yielded a single band of similar size to that of
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the wild-type (Figure 1). Sequencing of the 26 corresponding RT-PCR products revealed that all
were correctly spliced as per the wild-type. When quantitative RT-PCR analyses were performed,
a statistically significant lower mRNA expression level was observed with 4 of the 23 missense variants
but not with any of the synonymous variants (Table 1). In this regard, it is pertinent to point out that
the reliability of our quantitative RT-PCR method had been experimentally validated in our previous
study [4].
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Figure 1. Qualitative RT-PCR analyses of HEK293T cells transfected with the full-length gene
expression constructs carrying various SPINK1 exonic variants. The missense and synonymous variants
under study (Table 1) are highlighted in bold and underlining, respectively. The remaining variants,
all of which are clearly loss-of-function variants (i.e., translational initiation codon or frameshifting
variants), were not discussed in this study. Note that the previously studied c.194G>A variant [4] was
also included for the reason of completeness.
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The decrease in mRNA expression noted for the four missense variants may be explicable in terms
of two non-mutually exclusive mechanisms. Firstly, these variants could have led to the production
of aberrantly spliced transcripts but these aberrant transcripts may have been subjected to rapid
degradation by cellular defense mechanisms [14], rendering them undetectable by qualitative RT-PCR
analysis. Secondly, and as mentioned above, correctly spliced variant-containing transcripts may
be less stable as compared to wild-type through for example the formation of alternative mRNA
secondary structures [2]. Whichever, the two different mechanisms are indistinguishable by our
quantitative RT-PCR analysis.
Irrespective of the underlying biological mechanisms responsible, our systematic mRNA
expression analysis of known SPINK1 missense variants is suggestive of the existence of a new
layer of functional deficiency, at least in the case of two specific missense variants (i.e., c.190A>G
(p.Asn64Asp) and c.199C>T (p.Arg67Cys)), the pathogenicity of which had already been established
(Table 1). (N.B. The pathogenicity classifications of all 24 SPINK1 missense mutations (Table 1)
were based essentially upon the analysis of in vitro-expressed mutant proteins in terms of their
secretion and/or enzymatic activity.) Thus, the pathogenicity of these two variants may be seen
to emanate from a combination of defective mRNA expression and protein function. By contrast,
the other two missense variants characterized by a significant influence on pre-mRNA splicing
and/or mRNA stability were previously classified as being either non-pathogenic or ‘protective’
(Table 1). Our new data may therefore prompt a re-consideration of these initial variant classifications.
Specifically, the ‘non-pathogenic’ c.29G>A (p.Ser10Asn) variant may actually serve to increase the risk
of chronic pancreatitis through its impact on mRNA expression and/or stability. As for the c.203A>G
(p.Gln68Arg) variant, any ‘protective’ effect due to the significantly increased secretion of the mutant
protein may be partly compensated for by its negative effect on pre-mRNA splicing and/or stability.
This notwithstanding, two caveats should be borne in mind. First, the strongest observed effect on
pre-mRNA splicing and/or stability was a 23% reduction from normal (c.199C>T). Whether such
decreases are meaningful in a pathological context, particularly when we consider that the alleles
responsible occur only in the heterozygous state in their respective carriers, is unclear. Second, the
analyses should ideally be performed in a human pancreatic acinar cell line, which unfortunately is
not yet available.
4. Conclusions
In summary, we demonstrate that four (~17%) of the currently known 24 SPINK1 missense
variants exert a significant impact on pre-mRNA splicing and/or mRNA stability. However, since the
strongest effect observed was a 23% reduction from normal, the contribution of SPINK1 missense
variants to the clinical phenotype through their impact on mRNA processing is likely to be relatively
minor. Finally, to the best of our knowledge, this study is the first to comprehensively analyze the
consequences of all known missense mutations in a given gene on mRNA expression/stability in the
context of a full-length gene assay. It remains to be seen if comparable results will be obtained for
missense variants associated with other diseases.
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